Insider Selling: ResMed Inc. (NYSE:RMD) Insider Sells 9,745 Shares of Stock

ResMed Inc. (NYSE:RMD - Get Free Report) insider Kaushik Ghoshal sold 9,745 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $239.31, for a total value of $2,332,075.95. Following the transaction, the insider now directly owns 9,725 shares in the company, valued at $2,327,289.75. The trade was a 50.05 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Kaushik Ghoshal also recently made the following trade(s):

• On Monday, March 3rd, Kaushik Ghoshal sold 9,113 shares of ResMed stock. The stock was sold at an average price of $235.40, for a total value of $2,145,200.20.

ResMed Stock Down 4.7 %

Shares of NYSE:RMD traded down $11.16 on Tuesday, hitting $225.47. 1,272,116 shares of the company traded hands, compared to its average volume of 974,496. The stock has a 50 day simple moving average of $236.86 and a 200-day simple moving average of $240.13. The company has a quick ratio of 2.29, a current ratio of 3.33 and a debt-to-equity ratio of 0.13. The company has a market cap of $33.11 billion, a PE ratio of 26.62, a PEG ratio of 1.53 and a beta of 0.74. ResMed Inc. has a 52 week low of $172.19 and a 52 week high of $263.05.

Remove Ads

ResMed (NYSE:RMD - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. As a group, research analysts expect that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be given a $0.53 dividend. The ex-dividend date is Thursday, February 13th. This represents a $2.12 annualized dividend and a yield of 0.94%. ResMed's dividend payout ratio (DPR) is presently 25.03%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Menard Financial Group LLC purchased a new position in shares of ResMed during the fourth quarter valued at approximately $98,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in ResMed in the fourth quarter valued at about $19,540,000. ABLE Financial Group LLC grew its stake in shares of ResMed by 2.8% during the 4th quarter. ABLE Financial Group LLC now owns 2,639 shares of the medical equipment provider's stock valued at $604,000 after purchasing an additional 72 shares during the period. Forum Financial Management LP purchased a new position in shares of ResMed in the fourth quarter worth approximately $273,000. Finally, Toronto Dominion Bank increased its holdings in ResMed by 4.3% during the fourth quarter. Toronto Dominion Bank now owns 51,349 shares of the medical equipment provider's stock valued at $11,743,000 after buying an additional 2,099 shares during the last quarter. 54.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on RMD shares. KeyCorp increased their target price on ResMed from $266.00 to $280.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. UBS Group raised ResMed from a "hold" rating to a "strong-buy" rating in a report on Friday, January 31st. Stifel Nicolaus lowered their target price on shares of ResMed from $250.00 to $240.00 and set a "hold" rating on the stock in a research note on Wednesday, March 5th. The Goldman Sachs Group began coverage on shares of ResMed in a report on Thursday, January 16th. They issued a "buy" rating for the company. Finally, JPMorgan Chase & Co. boosted their price target on shares of ResMed from $270.00 to $286.00 and gave the stock an "overweight" rating in a research note on Friday, January 31st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, ResMed presently has a consensus rating of "Moderate Buy" and an average target price of $243.82.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.